Hutchmed (HCM) said Monday that the China National Medical Products Administration accepted the new drug application for fanregratinib as a potential treatment for adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma and gave the application priority review status.
The company said the application is backed by data from a phase 2 study in China, which met its primary endpoint of objective response rate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.